Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2018 | Pages:
70 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)
The U.S. intravenous immunoglobulin (IVIG) market size is expected to reach USD 5.04 billion by 2025, according to a new report by Grand View Research, Inc. The market is estimated to witness a noteworthy CAGR of 6.1% over the forecast period. Rising prevalence of primary and acquired immunodeficiency diseases such as congenital AIDS and hypogammaglobulinemia is a major growth driver of this market. Rising cases of primary immune deficiency diseases are expected to drive the demand for fast, accurate, and safe treatment options, thereby boosting the market growth. Other IVIG applications, such as neurological disorders, organ transplantation, peripheral neuropathies, and Alzheimer's disease, also provide a lucrative growth opportunity to the market players. Thus, growing cases of aforementioned diseases are also expected to increase the penetration of IVIG in the near future. Market participants are actively involved in R&D for the development of innovative drugs and discovering new therapeutic areas for the existing drugs. For instance, in 2017, Kedrion Biopharma, Inc. and Kamada Ltd. received approval from the U.S. FDA for their new product KEDRAB. Industry players are also involved in the development of new plasma collection centers and other collaborative strategies to expand their geographical reach and widen their product portfolio. For example, in June 2018, Shire plc received approval from the U.S. FDA for its new plasma manufacturing facility near Covington, Georgia, thereby increasing the company's production capacity. The expected product approvals in the coming years are anticipated to help fuel the market growth. Further key findings from the study suggest: • Hypogammaglobulinemia segment held the substantial share of around 20.0% based on application in 2017, owing to rising adoption of IgG intravenous and subcutaneous replacement therapies • Kawasaki diseases segment is expected to grow lucratively at a CAGR of 9.2% over the forecast period owing to increasing disease prevalence in U.S. • IVIG held the largest share of the route of administration segment of U.S. IG market owing to their high adoption in the treatment of immune deficiency diseases • Subcutaneous immunoglobulin is expected to witness the fastest CAGR of over 11% during the forecast period due to its benefits, such as shorter administration duration and fewer needle punctures • Hospital pharmacy held the largest share in 2017 owing to the presence of a large number of hospital pharmacies and easy availability of products in the hospitals.
Table of Contents
Chapter 1 Executive Summary
1.1 Market Snapshot
Chapter 2 Research Methodology & Scope
2.1 Country Market Calculation
2.1.1 Country Market: Base Estimates
2.1.2 Country Market: CAGR Calculation
2.2 List of Secondary Sources
Chapter 3 U.S. IVIG Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Rising prevalence of immunodeficiency diseases
3.2.2 Increasing adoption of immunoglobulin replacement therapy
3.2.3 Rising geriatric population
3.3 Market Restraint Analysis
3.3.1 Cost Intensive nature of immunoglobulin replacement therapy
3.3.2 Stringent regulations pertaining to production and approval
3.4 Penetration & Growth Prospect Mapping, by Application
3.5 Penetration & Growth Prospect Mapping, by Route of Administration
3.6 U.S. IVIG - SWOT Analysis, By Factor (political & legal, economic and technological)
3.7 Industry Analysis - Porter's
3.8 Company Market Share Analysis, 2017
Chapter 4 U.S. IVIG Market: Application Estimates & Trend Analysis
4.1 U.S. IVIG Market: Application Movement Analysis
4.2 Hypogammaglobulinemia
4.2.1 Hypogammaglobulinemia market estimates and forecasts, 2014 - 2025 (USD Million)
4.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
4.3.1 CIDP market estimates and forecasts, 2014 - 2025 (USD Million)
4.4 Immunodeficiency diseases
4.4.1 Immunodeficiency diseases market estimates and forecasts, 2014 - 2025 (USD Million)
4.5 Congenital AIDS
4.5.1 Congenital AIDS market estimates and forecasts, 2014 - 2025 (USD Million)
4.6 Chronic Lymphocytic Leukemia
4.6.1 Chronic lymphocytic leukemia market estimates and forecasts, 2014 - 2025 (USD Million)
4.7 Myasthenia gravis
4.7.1 Myasthenia gravis market estimates and forecasts, 2014 - 2025 (USD Million)
4.8 Multifocal Motor Neuropathy
4.8.1 Multifocal motor neuropathy market estimates and forecasts, 2014 - 2025 (USD Million)
4.9 Immune Thrombocytopenia Purpura (ITP)
4.9.1 ITP market estimates and forecasts, 2014 - 2025 (USD Million)
4.10 Kawasaki disease
4.10.1 Kawasaki disease market estimates and forecasts, 2014 - 2025 (USD Million)
4.11 Guillain-Barre syndrome
4.11.1 Guillain-Barre syndrome market estimates and forecasts, 2014 - 2025 (USD Million)
4.12 Others
4.12.1 Others market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 5 U.S. IG Market: Route of Administration Estimates & Trend Analysis
5.1 U.S. IG Market: Route of Administration Movement Analysis
5.2 Intravenous
5.2.1 Intravenous immunoglobulin market estimates and forecasts, 2014 - 2025 (USD Million)
5.3 Subcutaneous
5.3.1 Subcutaneous immunoglobulin market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 6 U.S. IVIG Market: Distribution Channel Estimates & Trend Analysis
6.1 U.S. IVIG Market: Distribution Channel Movement Analysis
6.2 Hospital Pharmacy
6.2.1 Hospital pharmacy market estimates and forecasts, 2014 - 2025 (USD Million)
6.3 Specialty Pharmacy
6.3.1 Specialty pharmacy market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 7 Competitive Landscape
7.1 Strategy Framework
7.2 Market participation categorization
7.3 Company Profiles
7.3.1 Biotest AG
7.3.1.1 Company overview
7.3.1.2 Financial performance
7.3.1.3 Product benchmarking
7.3.1.4 Strategic initiatives
7.3.2 Octapharma AG
7.3.2.1 Company Overview
7.3.2.2 Financial Performance
7.3.2.3 Product Benchmarking
7.3.2.4 Strategic Initiatives
7.3.3 Baxter
7.3.3.1 Company overview
7.3.3.2 Financial performance
7.3.3.2 Product benchmarking
7.3.4 LFB Biotechnologies
7.3.4.1 Company overview
7.3.4.2 Product Benchmarking
7.3.4.3 Strategic Initiatives
7.3.5 China Biologics Products, Holdings, Inc.
7.3.5.1 Company overview
7.3.5.2 Financial performance
7.3.5.3 Product benchmarking
7.3.5.4 Strategic Initiatives
7.3.6 Grifols, S.A.
7.3.6.1 Company Overview
7.3.6.2 Financial Performance
7.3.6.3 Product benchmarking
7.3.6.4 Strategic Initiatives
7.3.7 Kedrion Biopharma, Inc.
7.3.7.1 Company Overview
7.3.7.2 Financial Performance
7.3.7.3 Product benchmarking
7.3.7.4 Strategic Initiatives
7.3.8 CSL Behring
7.3.8.1 Company Overview
7.3.8.2 Financial Performance
7.3.8.3 Product benchmarking
7.3.8.4 Strategic Initiatives
7.3.9 BDI Pharma, Inc.
7.3.9.1 Company Overview
7.3.9.2 Product benchmarking
7.3.9.3 Strategic Initiatives
7.3.10 Shire
7.3.10.1 Company Overview
7.3.10.2 Financial Performance
7.3.10.3 Product benchmarking
7.3.10.4 Strategic Initiatives
7.3.11 Bio Products Laboratory Ltd.
7.3.11.1 Company Overview
7.3.11.2 Product benchmarking
7.3.11.3 Strategic Initiatives
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
